Clementia Pharmaceuticals
logo BDC

Clementia Pharmaceuticals

Clementia is a privately-held, clinical stage biotechnology company dedicated to the development and commercialization of treatments for people living with rare diseases. Clementia exploits the use of novel Retinoic acid receptor gamma agonists (RARγ) to address diseases of heterotopic ossification, including Fibrodysplasia Ossificans Progressiva.

Our partnership

Clementia is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.

Contact

Jean-François Pariseau, Founding Partner at Amplitude Venture Capital

Investment year:  2012
Industry sector:  Drugs
Region:  Quebec
Website
Follow Clementia Pharmaceuticals

Recent news

Canada’s biotech sector continues to build momentum with two large IPOs since March

Learn More
v17.9.0.10395